Davis Matthew W. 4

What Happened

• Matthew W. Davis, Chief Development Officer of Aquestive Therapeutics (AQST), was granted two awards on 2026-03-09: 50,000 restricted common shares and 50,000 derivative awards (an option-like award). Both awards were reported at a $0 acquisition price (i.e., granted as compensation).

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (filed within the typical two-business-day window, i.e., appears timely).
• Grants: 50,000 restricted shares (reported as Common Stock) and 50,000 derivative awards (reported as a derivative security); both reported at $0. Total reported acquisition value: $0.
• Vesting: Restricted shares and the derivative award vest in three annual installments — 25% at the 1st anniversary, 25% at the 2nd, and 50% at the 3rd (per footnotes F1 and F2).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Nature of transaction: Award/grant for compensation (A); not a purchase or sale of existing shares.

Context

• These are compensation grants, not open-market purchases or sales; such awards are routine for executive compensation and do not, by themselves, indicate trading intent. The derivative award is a grant with a vesting schedule (not an exercised option or immediate sale).